Drugs / BCG Organism
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03305341 | May 2025 → Nov 2026 expected | COVID-19 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Organism | “NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix” NCT03305341 ↗ |
| Modality | Vaccine | “BCG Vaccine Mix” NCT03305341 ↗ |